Compare Amgen, Inc. (AMGN) vs Grab Holdings Ltd. (GRAB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Grab Holdings Ltd. — how do they compare? Amgen, Inc. trades at $413.07 (market cap $225.71B), while Grab Holdings Ltd. trades at $3.74 (market cap $14.97B). The key difference: Amgen, Inc. is far larger — about 15.1× Grab Holdings Ltd.'s market cap, and Amgen, Inc. pays a 2.42% dividend while Grab Holdings Ltd. pays none. Which is the better fit depends on your goals.
| AMGN | GRAB | |
|---|---|---|
Market Cap | $225.71B | $14.97B |
Sector | Health | Technology |
52-Week High | $417.20 | $6.45 |
52-Week Low | $271.18 | $3.27 |
Enterprise Value | $269.02B | $10.70B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $410.95, up 1.51% today, near its pivot point of $408. The stock shows bullish momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $6.29 versus $5.62 expected. Revenue reached $36.75B in 2025, with a net income margin of 22.95%. Analyst consensus is bullish with a 58.98% buy rating, though the current price exceeds the consensus target of $394.69. Technical indicators signal an overbought condition with RSI above 75.
Outlook remains positive driven by robust product growth and raised 2026 guidance, but risks include high valuation multiples, significant debt levels, and competitive pressures. The stock's proximity to resistance at $415 suggests near-term consolidation may occur, yet fundamental strength supports long-term upside potential for investors focused on biotech growth.
GRAB trades at $3.66, down 0.27% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $3.37B in 2025, with net income turning positive at $268M, reflecting improved profitability. The company raised its 2026 guidance, supported by growth in on-demand and financial services segments. Analyst sentiment is overwhelmingly positive, with 91.67% recommending Buy.
Outlook remains favorable due to sustained revenue growth and margin expansion, but risks include high valuation multiples and insider selling. The stock offers upside to the average price target of $5.86, though volatility from competitive pressures and macroeconomic headwinds warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →
